# CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

> **NCT01653158** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 46 (actual)

## Conditions studied

- Advanced Non-Hematologic Malignancies

## Interventions

- **DRUG:** CP-751,871
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01653158
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653158, "CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01653158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*